TīmeklisFind out the direct holders, institutional holders and mutual fund holders for Kymera Therapeutics, Inc. (KYMR).
Did you know?
Tīmeklis2024. gada 6. jūl. · WATERTOWN, Mass., July 06, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public … Tīmeklis2024. gada 3. nov. · Raised $150 million through private placement equity financing; September 30, 2024, cash balance of $596 million. Company to hold quarterly results call at 8:30 a.m. EST (800-715-9871) WATERTOWN ...
TīmeklisKymera Therapeutics, Inc. (KYMR) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Add to watchlist 29.59 -2.10 (-6.63%) At close: 04:00PM EST 29.00 -0.59 ( … Tīmeklis2024. gada 23. febr. · 23 February 2024, 10:13 am · 2-min read. CLEVELAND, February 23, 2024 -- ( BUSINESS WIRE )--The Women in Manufacturing Education Foundation (WiMEF) is pleased to announce the election of 21 members to its 2024 Board of Directors, whose terms begin on April 1, 2024. The board is led by Chair Veronica …
Tīmeklis2024. gada 11. apr. · Kymera Therapeutics, Inc. WATERTOWN, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein ... Tīmeklis2024. gada 23. febr. · Kymera Therapeutics, Inc. (KYMR) NasdaqGM - NasdaqGM Real-time price. Currency in USD Add to watchlist 31.53 +0.81 (+2.64%) At close: …
Tīmeklis2024. gada 23. febr. · Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of ...
Tīmeklis2024. gada 9. apr. · All of the below ideas for biotech stocks to buy should be considered speculative. However, they also have potential catalysts that can see them produce 100% returns. XNCR. Xencor. $28.86. christmas creek iron ore mineTīmeklisFind the latest Kymera Therapeutics, Inc. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing. germany security councilTīmeklisWALTHAM, Mass., January 31, 2024--X-Chem, the leading provider of innovative solutions in early-stage drug discovery, expands collaboration with Kymera Therapeutics, Inc. Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in ... germany seasonsTīmeklis2024. gada 16. marts · WATERTOWN, Mass., March 16, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elena Ridloff, CFA, to its … germany secretary of defenseTīmeklis2024. gada 9. marts · finance.yahoo.com - February 23 at 9:03 AM: Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 23 finance.yahoo.com - February 1 at 8:55 AM: X-Chem and Kymera Expand Existing Partnership finance.yahoo.com - January 31 at 8:41 AM: We're Hopeful … germanys economy during ww1TīmeklisFind out all the key statistics for Kymera Therapeutics, Inc. (KYMR), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. germany second hand super carsTīmeklisGet the latest Kymera Therapeutics, Inc. (KYMR) stock news and headlines to help you in your trading and investing decisions. germany select